NCT06734637

Efficacy and Safety of Peginterferon in ET and PV.

A Single-arm, Single-center Study to Explore the Safety and Efficacy of Pegylated Interferon Alpha in Chinese Patients With ET (Essential Thrombocythemia) and PV (Polycythemia Vera).

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Zhenya Hong · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Eligible participants will receive a subcutaneous injection of Peginterferon α-2b 180 mcg once a week and follow-up，and efficacy and safety will be evaluated.

Conditions

• Essential Thrombocythemia
• Polycythemia Vera

Interventions

Type	Name	Description
DRUG	Peginterferon α-2b injection	Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).

Timeline

• Start date: 2024-11-20
• Primary completion: 2026-11-20
• Completion: 2027-11-20
• First posted: 2024-12-16
• Last updated: 2024-12-16

Locations

1 site across 1 country: China